Study of WX390 and Toripalimab for advanced cervical cancer
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests a combination of two drugs, WX390 and Toripalimab, against standard treatments for recurrent or metastatic cervical cancer that has worsened after platinum-based chemotherapy. It aims to find a more effective treatment option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have recurrent or metastatic cervical cancer that has not been cured by standard treatments.
- You must be between 18 and 75 years old.
- You must agree to provide a fresh or stored tumor sample for testing.
- You must be able to swallow tablets and have a life expectancy of at least 3 months.
- You cannot have received certain targeted therapies before, or have certain medical conditions like diabetes or lung disease.
- You must not have active infections, bleeding, or severe digestive issues.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two investigational drugs, WX390 and Toripalimab, for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if this combination can shrink tumors or slow their growth.
This trial tests a combination of an experimental pill (WX390) and an immunotherapy drug (Toripalimab) for a specific type of cervical cancer that has an STK11 gene change. It aims to see if this combination can shrink tumors or slow the cancer.
This trial tests a combination of two drugs, utidelone and toripalimab, for people with advanced cervical cancer that has come back or spread. The goal is to see if this treatment can shrink tumors or slow the disease.
This trial tests a combination of the immunotherapy drug toripalimab with chemotherapy for women with locally advanced cervical cancer that has not been treated yet. The goal is to see if this approach can shrink tumors before standard radiation therapy.
This trial tests a new drug called WX390 for people whose advanced solid tumors have not responded to standard treatments. The study aims to see if WX390 can help shrink or slow the growth of these tumors.
This trial combines the immunotherapy drug toripalimab with standard chemoradiation to treat newly diagnosed advanced cervical cancer. It aims to see if adding toripalimab improves outcomes for patients whose cancer has not spread to distant organs.
Hear when a new Cervical Cancer Metastatic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.